News
BIIB
203.28
+0.41%
0.82
BIIB June 7th Options Begin Trading
NASDAQ · 6h ago
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
NASDAQ · 9h ago
EMA SAYS CHMP ADOPTED POSITIVE OPINIONS FOR TOFIDENCE (TOCILIZUMAB)
Reuters · 11h ago
BIOGEN INC <BIIB.O>: GUGGENHEIM CUTS TARGET PRICE TO $255 FROM $275
Reuters · 11h ago
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)
TipRanks · 12h ago
Buy Rating Justified: Biogen’s Promising Drug Launches and Strategic Growth Initiatives
TipRanks · 15h ago
Biogen’s Surpassing Performance and Positive Outlook Affirm Buy Rating
TipRanks · 16h ago
Biogen’s Financial Upswing: Strong Q1 Performance and Market Penetration Justify Buy Rating
TipRanks · 16h ago
Biogen's Tofidence Gets Positive CHMP Opinion For Rheumatoid Arthritis,Juvenile Arthritis & COVID-19
NASDAQ · 20h ago
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
NASDAQ · 1d ago
Biogen Price Target Cut to $200.00/Share From $215.00 by Barclays
Dow Jones · 1d ago
Biogen Is Maintained at Equal-Weight by Barclays
Dow Jones · 1d ago
Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $200
Benzinga · 1d ago
Biogen Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 1d ago
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
The European Medicines Agency has recommended the intravenous formulation of TOFIDENCE for approval for the treatment of rheumatoid arthritis. TofIDENCE is a biosimilar monoclonal antibody referencing ROACTEMRA. The drug is being developed by Biogen Inc.
Barchart · 1d ago
Stock Market News for Apr 25, 2024
NASDAQ · 1d ago
These Analysts Revise Their Forecasts On Biogen After Q1 Results
Biogen reported first-quarter adjusted EPS of $3.67, up 8%. The company reported sales of $2.29 billion, down 7% year over year. Biogen shares gained 4.6% to close at $201.99 on Wednesday after the company reported better-than-expected earnings.
Benzinga · 1d ago
Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday
Rosenblatt raised the price target for Meta Platforms, Inc. (NASDAQ:META) on Wednesday. The price target was raised from $520 to $562 for the company. Other analysts raised the target for SLM Corporation and cut the price for Biogen Inc.
Benzinga · 1d ago
Biogen Is Maintained at Neutral by Wedbush
Dow Jones · 1d ago
Biogen Price Target Raised to $215.00/Share From $213.00 by Wedbush
Dow Jones · 1d ago
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.